Pharming Group N.V. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K reports the preliminary (unaudited) financial results and business update for Pharming Group N.V. for the second quarter and first half of the year ended June 30, 2025. The company is a global biopharmaceutical firm focused on rare diseases, headquartered in Leiden, The Netherlands. Key commercial assets include RUCONEST® (for hereditary angioedema) and Joenja® (leniolisib, for APDS).
Key Financial Metrics
| Metric | 2Q 2025 | 2Q 2024 | 1H 2025 | 1H 2024 |
|---|---|---|---|---|
| Total Revenues | $93.2M | $74.1M | $172.3M | $129.7M |
| Gross Profit | $84.2M | $66.1M | $155.0M | $113.3M |
| Operating Profit (Loss) | $10.8M | ($3.1M) | $3.8M | ($19.4M) |
| Net Profit (Loss) | $4.6M | ($1.2M) | ($10.3M) | ($13.7M) |
| Cash & Marketable Securities | $130.8M (as of June 30, 2025) | |||
| Operating Cash Flow | $11.7M | ($13.2M) | $12.0M | ($20.9M) |
Revenue Breakdown (2Q 2025): RUCONEST® generated $80.4M (28% YoY growth); Joenja® generated $12.8M (15% YoY growth). The U.S. market accounted for 92% of Joenja® revenue.
Material Changes vs. Prior Period
- Profitability Turnaround: The company achieved an operating profit of $10.8M in 2Q 2025, reversing a $3.1M loss in the same period last year. This was driven by significant revenue growth and cost management, despite $2.1M in non-recurring Abliva acquisition expenses.
- Revenue Growth: Total revenue grew 26% in 2Q 2025 and 33% in 1H 2025, primarily due to volume increases in RUCONEST® and price/volume improvements in Joenja®.
- Acquisition Impact: Pharming acquired 100% of Abliva AB in June 2025. Total acquisition-related costs of $15.0M were incurred in 1H 2025, including $9.9M in non-recurring expenses and $66.1M in cash purchases of shares.
- Finance Result: Net finance results declined to a $4.0M loss in 2Q 2025 from a $3.4M gain in 2Q 2024, largely due to the absence of a one-time fair value gain recognized in the prior year and unfavorable EUR/USD exchange rate movements.
Guidance, Outlook, and Risks
- 2025 Guidance Raised: Full-year 2025 revenue guidance increased to $335M–$350M (previously $325M–$340M). Operating expenses are expected to be $304M–$308M, assuming constant currency and including $10.2M in non-recurring Abliva expenses.
- Strategic Catalysts:
- Joenja® Expansion: A study published in Cell suggests APDS prevalence could be 100x higher than previously thought, potentially reclassifying Variants of Uncertain Significance (VUS) patients. This could significantly expand the addressable market starting in 2H 2025.
- Regulatory Milestones: Submitted NDA for leniolisib in Japan (decision expected in 9 months); on track for pediatric sNDA submission to FDA in 3Q 2025; UK launch completed with first patients on therapy.
- Pipeline: KL1333 (mitochondrial disease) pivotal FALCON trial is progressing with wave two dosing; read-out expected in 2027.
- Risks and Contingencies:
- Tariffs: Management is monitoring U.S. tariffs but does not expect a material impact on the business.
- Currency: Unfavorable EUR/USD fluctuations impacted finance results.
- Going Concern: The Board has assessed the company as a going concern with sufficient funding for at least 12 months.
Investor Verification Checklist
- Revenue Sustainability: Verify the durability of the 26% revenue growth rate, specifically the contribution from RUCONEST® volume vs. pricing.
- APDS Prevalence Data: Assess the commercial impact of the Cell study findings regarding VUS reclassification and the 100x prevalence estimate.
- Abliva Integration: Monitor the integration of Abliva AB and the progress of the KL1333 FALCON trial, given the significant capital outlay ($66.1M cash purchase).
- Regulatory Timelines: Track the status of the Japan NDA and the pediatric sNDA submission for leniolisib, as these are critical for future growth.
- Cash Burn vs. Generation: Confirm that operating cash flow generation ($12.0M in 1H) remains sufficient to fund R&D and pipeline development without further dilution or debt issuance.